Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
Matching articles
Showing 49–60 of 134 articles · Explore study findings
- Explore study findings
What patients and blinded evaluators saw after laser resurfacing
GHK-Cu is the copper complex of a three-amino-acid peptide. An older randomized study published in 2006 examined whether products containing this complex changed recovery or appearance after carbon dioxide laser resurfacing. Thirteen participants completed the study.
GHK-Cu1 source (2006)
- Explore study findings
What Japan's diagnostic approval covers
GHRP-2 is a synthetic six-residue peptide, also called pralmorelin, that stimulates growth hormone (GH) release through the growth hormone secretagogue system. Japan approved a pralmorelin hydrochloride product as a diagnostic agent for evaluating impaired GH secretion.
GHRP-22 sources (2007, 2025)
- Explore study findings
Why preventing a raised scar differs from reversing one
GHRP-6 is a synthetic six-residue peptide that activates the ghrelin receptor and promotes growth hormone release in experimental settings. An animal study asked whether exposure to GHRP-6 changed the development of a raised scar or the appearance of an already mature scar.
GHRP-62 sources (2018, 2021)
- Explore study findings
Why a human blood study reported two half-lives
GHRP-6 is a six-residue synthetic growth hormone–releasing peptide. In a small human study, researchers asked which mathematical model best described the decline of GHRP-6 itself in blood. No recent primary human study directly repeating this time-course experiment was identified.
GHRP-61 source (2012)
- Explore study findings
Why Copper’s Chemical Form Matters When Reading GLOW Research
Peptides are short chains made by linking amino acids through peptide bonds. A chain can sometimes bind a metal ion. That is the case for GHK-Cu, the copper complex of a three-amino-acid peptide and one ingredient named in descriptions of GLOW.
GLOW Blend1 source (2026)
- Explore study findings
What a Copper Peptide Hydrogel Study Adds to the GLOW Discussion
GLOW is a label for a mixture of research materials that can include GHK-Cu, a peptide bound to copper. A 2026 paper used GHK-Cu in an engineered hydrogel for an infected diabetic wound model.
GLOW Blend1 source (2026)
- Explore study findings
What a Mouse Mitochondria Study Can Explain About One GLOW 2 Ingredient
GLOW 2, as described in the catalog, includes a material named MOTS-c alongside GHK-Cu and BPC-157. The exact blend formulation remains unconfirmed.
GLOW 2 Blend1 source (2026)
- Explore study findings
What the 2026 MOTS c Appraisal Means for Claims About GLOW 2
The GLOW 2 formulation described in the catalog names the mitochondrial peptide MOTS-c together with GHK-Cu and BPC-157. The exact preparation has not been confirmed. Federal documents that discuss MOTS-c provide useful context for assessing what is known about that ingredient.
GLOW 2 Blend2 sources (2026)
- Explore study findings
What three semaglutide trials tell us about kidney outcomes
Semaglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. It is used in several approved formulations for specific conditions.
GLP-1 SEMA2 sources (2026)
- Explore study findings
What BARI-STEP found after bariatric surgery
Semaglutide is a modified GLP-1 receptor agonist peptide. In the 2026 BARI-STEP trial, researchers tested whether it affected body weight in adults who had lost less weight than the study’s threshold after bariatric surgery.
GLP-1 SEMA2 sources (2026)
- Explore study findings
What two Alzheimer’s trials found about oral semaglutide
Semaglutide is a modified GLP-1 receptor agonist. Researchers investigated whether its oral form could slow progression in people with early symptomatic Alzheimer’s disease. Two phase 3 trials reported in 2026 compared it with placebo.
GLP-1 SEMA2 sources (2026)
- Explore study findings
What a 2026 analysis found across sleep apnea subgroups
Tirzepatide is a modified peptide that activates the GIP and GLP-1 receptors. “GLP-2 TIRZ” is the catalog label. Tirzepatide’s tested targets are GIP and GLP-1, distinct from the GLP-2 receptor. A 2026 analysis asked how sleep apnea outcomes varied with participants’ starting characteristics.
GLP-2 TIRZ3 sources (2022–2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
